On June 11, 2015 Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry and McGill University, one of the world’s leading post-secondary institutions, have entered into multiple research agreements designed to discover novel modulators for promising biological targets of pharmacological interest (Press release, Cyclenium, JUN 11, 2015, View Source [SID1234517246]). Involving investigators from the Rosalind and Morris Goodman Cancer Research Centre (GCRC), the Departments of Biochemistry and Physiology, and the McGill High Throughput Screening (HTS) facility, these collaborations will provide McGill researchers with immediate access to Cyclenium’s proprietary QUEST Library of next generation macrocyclic molecules and associated optimization capabilities. The initial objective of these exploratory efforts is to identify macrocyclic compounds capable of interacting with specific therapeutic targets, including several involving protein-protein interactions, being studied in the various McGill laboratories, thereby providing tools to improve the understanding of their involvement in various disease states, with the longer term goal of discovering novel pharmacological or diagnostic agents acting at these targets.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We have been greatly impressed with the nature and quality of the research being pursued within McGill’s laboratories and feel strongly that our macrocyclic compounds will be of significant assistance in advancing their studies," stated Helmut Thomas, Ph.D., President & Chief Executive Officer of Cyclenium. "Coupling the cutting-edge efforts and the world class expertise of their investigators with our CMRT Technology and proven development success in the macrocycle arena offers an excellent opportunity for synergy in the discovery and development of novel therapeutic and diagnostic agents against important, but difficult, pharmacological targets."
"We are excited about our collaboration with Cyclenium," said Dr. Morag Park, Director of the Rosalind and Goodman Cancer Research Centre, McGill University, "as it will continue to create new opportunities to accelerate the translation of basic research and our mechanistic understanding of cancer biology into potential therapies for cancer patients."
"The partnership with Cyclenium will provide our researchers access to new chemical probes with which we can query the mechanics of life at the molecular level," said Dr. Albert Berghuis, Chair of the Biochemistry Department, McGill University. "There is no doubt that the basic insights gained will lead to new avenues for therapy development for a host of diseases. This is therefore a win-win-win scenario for McGill, Cyclenium, and ultimately patients."
"This collaborative venture is a prime example of harnessing the biomedical expertise of publicly funded university researchers with the technical prowess and resources of the biopharmaceutical industry to enhance drug discovery and disease treatment," said Dr. John Orlowski, Chair of the Department of Physiology, McGill University. "Such relationships will ultimately benefit not only the healthcare of Canadians but also individuals world-wide."